ARTV - Artiva Biotherapeutics, Inc. Company Long-Term Liabilities

Public company logo of artivabio.com (ARTV)

Artiva Biotherapeutics, Inc. (ARTV) attracts leading bioengineers through a stock option system, ensuring a stable workforce for new trials. The business relies on the development of NK-cell therapies to combat tumors, leveraging partnerships with industry behemoths. This market valuation chart shows long-term debt at 0.01. The firm's innovations enable the implementation of a ready-made umbilical cord blood therapy system, eliminating dependence on donor searches.

Artiva Biotherapeutics, Inc. (ARTV) Company Long-Term Debt: for the period 07/20/2024 - 11/01/2026

Artiva Biotherapeutics (ARTV) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price Artiva Biotherapeutics Inc.|ARTV - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Artiva Biotherapeutics|ARTV - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Artiva Biotherapeutics|ARTV - Company Book Value|Market Value to Book Value artivabio.com|ARTV - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Artiva Biotherapeutics, Inc.|ARTV - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Artiva Biotherapeutics Inc.|ARTV - Company Total Debt|Debts to Book Capitalization Artiva Biotherapeutics|ARTV - Company Long-Term Debt|Company Short-Term Loans and Borrowings Artiva Biotherapeutics|Immediate Liquidity artivabio.com
- earnings and market multiples details:
ARTV - Net Profit
Fundamental company valuation:ARTV (Artiva Biotherapeutics, Inc.)
Brand item of Artiva

Artiva Biotherapeutics, Inc. (ARTV) focuses on developing innovative NK-cell therapies, where long-term liabilities determine the capacity to fund costly research and development without patient hospitalization. Analyzing the organization's long-term financial debt allows for an assessment of the balance between credit risk and investment potential: a reduction in debt confirms stability, whereas stagnant borrowing may signal a slowdown in expansion within the autoimmune disease segment.

Competitors of Artiva Biotherapeutics, Inc. (ARTV)

ONC: Company Long-Term Indebtedness|Halozyme - Company Long-Term Debts|Revolution Medicines Inc (RVMD) - Company Long-Term Liabilities|AAPG: Company Long-Term Debts|Long-Term Debt CG Oncology Therapeutics (CGON)|Company Long-Term Debt UroGen Pharma Ltd.|BCAX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities PSNL (Personalis)|ERAS (Erasca Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts DCTH (Delcath)|YMAB - Company Long-Term Liabilities|AURA: Company Long-Term Liabilities|CADL - Company Long-Term Debts|Accuray (ARAY) - Company Long-Term Debt|SELLAS Life Sciences Group - Company Long-Term Loans and Borrowings|ACTU (Actuate Therapeutics, Inc) - Company Long-Term Debts|Long-Term Debt Citius Oncology Inc CTOR|Company Long-Term Debts HURA|Company Long-Term Debts protaratx.com (TARA)|Company Long-Term Debt Fate Therapeutics FATE|Company Long-Term Loans and Borrowings WHWK|TCRX: Company Long-Term Liabilities|Champions Oncology - Amount of Long-Term Liabilities|XBIT: Company Long-Term Debts|CVM - Long-Term Debt Volume|Company Long-Term Liabilities OSTX|Company Long-Term Debt RADX|Company Long-Term Debts ANL|Company Long-Term Debts Veru Corporation (VERU)|Tempest Therapeutics - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings XLO|Enochian BioSciences - Company Long-Term Debts|MURA: Company Long-Term Debt|KAPA: Company Long-Term Debts|OKUR - Long-Term Debt Volume|Company Long-Term Debt CytoMed Therapeutics Ltd|Long-Term Debt Curis Corp CRIS|Company Long-Term Liabilities APLM (Apollomics, Inc.)|Amount of Long-Term Liabilities THAR|Company Long-Term Debts ADVB (Advanced Biomed)|Company Long-Term Loans and Borrowings GNPX|Calidi Bio - Company Long-Term Debts|Long-Term Debt Sunshine Biopharma Inc.|xeneticbio.com (XBIO) - Company Long-Term Debt|Salarius Pharmaceuticals Inc - Company Long-Term Loans and Borrowings|PPBT (Purple Biotech Corp) - Company Long-Term Debts|Company Long-Term Debts AON|Company Long-Term Debt BeiGene, Ltd. (BGNE)|CKPT: Long-Term Liabilities|Company Long-Term Debts ELEV (Elevation Oncology, Inc.)|iCAD Inc. (ICAD) - Long-Term Debt|IKNA: Company Long-Term Liabilities|NTBL - Company Long-Term Debts|VIRX (viracta.com) - Company Long-Term Liabilities|MOR: Amount of Long-Term Liabilities|NAYA (NAYA Biosciences Inc.) - Company Long-Term Debts|Ascentage Pharma Group International (AAPGV) - Long-Term Debt Volume